Evotec Secures US Government Contract For Orthopoxvirus Antibody
Portfolio Pulse from Vandana Singh
Evotec SE's subsidiary, Just - Evotec Biologics Inc, has been awarded a contract worth up to $74 million by the U.S. Department of Defense for the development of monoclonal antibody-based drug product prototypes targeting orthopoxviruses. The contract includes discovery activities and the execution of Phase 1 first-in-human trials. This follows a previous contract awarded in September 2022 for developing antibodies against plague. Additionally, Evotec has ongoing partnerships with Sanofi SA's Sandoz and Bristol Myers Squibb Co.
July 05, 2023 | 11:45 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bristol Myers Squibb's partnership with Evotec could potentially benefit from the latter's new contract with the U.S. DOD.
Bristol Myers Squibb's partnership with Evotec could potentially benefit from the latter's new contract, which could boost Bristol Myers Squibb's stock.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
Evotec's new contract with the U.S. DOD and ongoing partnerships with major pharmaceutical companies could boost its stock in the short term.
The new contract from the U.S. DOD, along with Evotec's existing partnerships, could increase investor confidence and drive up the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Evotec's new contract with the U.S. DOD and ongoing partnerships with major pharmaceutical companies could boost its stock in the short term.
The new contract from the U.S. DOD, along with Evotec's existing partnerships, could increase investor confidence and drive up the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Sanofi's partnership with Evotec could potentially benefit from the latter's new contract with the U.S. DOD.
Sanofi's partnership with Evotec could potentially benefit from the latter's new contract, which could boost Sanofi's stock.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50